Critical Mass Strain
The CBD Critical Mass strain contains equal amounts of CBD, THC and 7%. This is low for THC but high for CBD. This winning combination creates a numbing sensation which leaves patients feeling focused and creative, but also a little sluggish.
This makes CBD Critical Mass a great strain for night and evening use. You won’t feel the need to work or run errands after you have settled in with CBD Critical Mass. CBD Critical Mass cannabis seeds have a high level of CBD that works with THC to increase potency and reduce the psychoactive effects of THC. CBD Critical Mass cannabis seeds offer purely medicinal benefits and no psychoactive effects.
Strain Effects
Critical Mass can be used medicinally to treat pain. This includes chronic or recurring pain. People who are going through chemotherapy, radiation or dealing with anorexia will find the strain stimulating their appetites and reducing their nausea. Relaxing properties of the strain can help ease anxiety and stress, and induce a deep sleep. CBD Critical Mass provides relief for hours.
Uses for critical mass
For patients with mood disorders or pain, Critical Mass can do wonders. It is able to relieve pain quickly and effectively. Its ability to relieve stress and other symptoms associated with chronic stress (such tight muscles or mood disorders) is second best. Critical Mass is a great option for people who struggle to sleep, regardless of whether it’s related to stress.
As well as inflammation, Critical Mass can also be used to treat depression and other mood disorders. As always, consult your doctor before self-medicating.
Using Critical Mass can help with the following conditions:
- Pain
- Stress
- Insomnia
- Depression
- Other mood disorders
- Inflammation
The dense buds are highly susceptible to mold, so it is important to watch what you do. In 45 to 55 days, indoor growers will be able to harvest 675 – 775 gr/m2. In the northern hemisphere, outdoor plants should yield between 500 and 600 grams per plant by September.
Reviews
There are no reviews yet.